Breaks Categories: News

TuesdayMar 05, 2024 3:41 pm

NetworkNewsBreaks – Mushrooms Inc. (MSRM) Announces Latest Product Launches, Development Collaboration in Germany

Mushrooms (OTC: MSRM), a developing leader in biotechnology and sustainable healthcare innovation using mushrooms and mycelium, today announced a suite of strategic initiatives aimed at transforming the healthcare landscape. These efforts, which underscore Mushrooms Inc.’s commitment to innovation, sustainability and the advancement of global health, include the launch of two groundbreaking health supplements, LONGEVITY and SPORT+, as well as the exploration of a development collaboration with a renowned scientific team in Germany. “We are at an exciting juncture in our journey,” said Mushrooms Inc. CEO Kimberly Carlson. “Our latest product launches and the collaboration in Germany are pivotal steps towards…

Continue Reading

TuesdayMar 05, 2024 3:36 pm

NetworkNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Announces Participation at Tomorrow’s Emerging Growth Conference

SenesTech (NASDAQ: SNES), the rodent-fertility control experts and inventors of ContraPest(R), the only EPA-registered contraceptive for male and female rats, will be presenting at the Emerging Growth Conference, which is scheduled for March 6, 2024. According to the announcement, key company leaders will deliver a webcast presentation; the presentation will include time for a Q&A. The presentation is slated to begin at 1:10 p.m. ET. An archived replay of the presentation will be available on the Emerging Growth YouTube channel following the webcast. In addition, SenesTech representatives will be available for one-on-one investor meetings. To view the presentation, visit https://nnw.fm/Bz6bz…

Continue Reading

TuesdayMar 05, 2024 3:23 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and in combination. The contract for the study was awarded to a third-party, Health Canada-licensed research laboratory. Manufacturing of the compositions for the first eight of the 12 study arms has been completed, and those arms will commence as soon as possible at the testing laboratory, expected to begin within 45 days. Each arm of the study will be dosed for…

Continue Reading

TuesdayMar 05, 2024 3:10 pm

NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy…

Continue Reading

TuesdayMar 05, 2024 3:01 pm

NetworkNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Adds Two New Dealers to Growing Distributorship Network

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced that its subsidiary, Bollinger Motors, is expanding its footprint. The company has named an additional two dealership groups as it rolls out its commercial truck line. The two dealership groups — Nacarato Truck Centers and Nuss Truck and Equipment — span seven states and include 11 locations. A U.S.-based company headquartered in Michigan, Bollinger Motors develops all-electric commercial chassis cab trucks. The company is beginning its rollout with its B4 Chassis Cab, an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input, which…

Continue Reading

TuesdayMar 05, 2024 2:46 pm

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, March 20, 2024, HeartBeam executives will also provide regulatory updates, reviewing ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, Consulting CFO Richard Brounstein, and VP of Regulatory Affairs Deborah Castillo, PhD, will host the call, followed by…

Continue Reading

TuesdayMar 05, 2024 2:30 pm

NetworkNewsBreaks — SOBR Safe Inc. (NASDAQ: SOBR) Reports ‘Dual Adoption’ of Proprietary Technology as Existing Behavioral Health Customer Expands Use

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, is collaborating with an existing behavioral health customer to expand the use of its proprietary SOBRsafe(TM) technology. SOBRSafe announced that the customer, which is not named for patient privacy reasons, has adopted the SOBRsure wearable band for continuous monitoring in an outpatient scenario; the customer had previously installed SOBRcheck in one of its facilities for point-of-care screening. “This customer is consistent with our approach to the behavioral health market — sign providers with multiple uses for our technology, prove its efficacy and expand within the account,” said SOBRsafe chair and…

Continue Reading

TuesdayMar 05, 2024 1:55 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North America. Represented by its senior research and clinical development team and co-authored by several of its esteemed scientific advisors, FSD shared the results of its phase 1 clinical study. The results were displayed in a…

Continue Reading

TuesdayMar 05, 2024 1:35 pm

NetworkNewsBreaks – Zoned Properties Inc. (ZDPY) Marks Pivotal Step in Scaling D2C Real Estate Portfolio

Zoned Properties (OTCQB: ZDPY), a technology driven property investment company for emerging and highly regulated industries, including legalized cannabis, today announced that it has listed its cultivation property in Chino Valley, Arizona (the “Chino Valley Property”) for sale at a purchase price of $16 million. The potential transaction marks a significant development in the company’s strategic real estate portfolio optimization. “As part of our ongoing strategic review to enhance shareholder value, we are very pleased to announce our intention to sell our Chino Valley Property. The Chino Valley Property, which we now consider a non-core asset to our investment strategy,…

Continue Reading

MondayMar 04, 2024 2:38 pm

NetworkNewsBreaks – BioVie Inc. (NASDAQ: BIVI) to Secure ~$21M in Public Offering

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. The company today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or pre-funded warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable for a period of five years following the date…

Continue Reading